<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://www.neurozone.org/wiki/lib/exe/css.php?s=feed" type="text/css"?>
<rdf:RDF
    xmlns="http://purl.org/rss/1.0/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:dc="http://purl.org/dc/elements/1.1/">
    <channel rdf:about="https://www.neurozone.org/wiki/feed.php">
        <title>NeuroZone</title>
        <description></description>
        <link>https://www.neurozone.org/wiki/</link>
        <image rdf:resource="https://www.neurozone.org/wiki/lib/exe/fetch.php?media=wiki:dokuwiki.svg" />
       <dc:date>2026-08-15T12:29:22+00:00</dc:date>
        <items>
            <rdf:Seq>
                <rdf:li rdf:resource="https://www.neurozone.org/wiki/doku.php?id=success&amp;rev=1785703830&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.neurozone.org/wiki/doku.php?id=pd&amp;rev=1785703461&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.neurozone.org/wiki/doku.php?id=imaging&amp;rev=1785703368&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.neurozone.org/wiki/doku.php?id=ccm&amp;rev=1785703268&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.neurozone.org/wiki/doku.php?id=epilepsy&amp;rev=1665368525&amp;do=diff"/>
            </rdf:Seq>
        </items>
    </channel>
    <image rdf:about="https://www.neurozone.org/wiki/lib/exe/fetch.php?media=wiki:dokuwiki.svg">
        <title>NeuroZone</title>
        <link>https://www.neurozone.org/wiki/</link>
        <url>https://www.neurozone.org/wiki/lib/exe/fetch.php?media=wiki:dokuwiki.svg</url>
    </image>
    <item rdf:about="https://www.neurozone.org/wiki/doku.php?id=success&amp;rev=1785703830&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-08-02T20:50:30+00:00</dc:date>
        <dc:creator>sflitman (sflitman@undisclosed.example.com)</dc:creator>
        <title>success - [Our Proud History] </title>
        <link>https://www.neurozone.org/wiki/doku.php?id=success&amp;rev=1785703830&amp;do=diff</link>
        <description>Our Proud History

We are a clinical research site founded in 2001 by Stephen Flitman, MD, a board-certified neurologist who trained at the Barrow Neurological Institute (Phoenix, Arizona) and completed his fellowship in Cognitive Neuroscience at the prestigious National Institutes of Health (Bethesda, Maryland). He served as first Associate Director then Director of Cognitive Neurology Section at Barrow until 2001. 
&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
&lt;br&gt;</description>
    </item>
    <item rdf:about="https://www.neurozone.org/wiki/doku.php?id=pd&amp;rev=1785703461&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-08-02T20:44:21+00:00</dc:date>
        <dc:creator>sflitman (sflitman@undisclosed.example.com)</dc:creator>
        <title>pd</title>
        <link>https://www.neurozone.org/wiki/doku.php?id=pd&amp;rev=1785703461&amp;do=diff</link>
        <description>Parkinson&#039;s Disease

With the advent of major organizations like the Michael J. Fox Foundation, Parkinson&#039;s research has never been busier.  Current trials have focused on new symptomatic therapies and new methods of early diagnosis.

No current studies in PD are available.
&lt;!--

^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator  ^  Duration  ^  Open Label Extension  ^
| New Onset Parkinson&#039;s Disease | Novel Oral Dopamine Agonist |  III  |  No   |  Placebo  |  24 weeks  |  9 months  |…</description>
    </item>
    <item rdf:about="https://www.neurozone.org/wiki/doku.php?id=imaging&amp;rev=1785703368&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-08-02T20:42:48+00:00</dc:date>
        <dc:creator>sflitman (sflitman@undisclosed.example.com)</dc:creator>
        <title>imaging</title>
        <link>https://www.neurozone.org/wiki/doku.php?id=imaging&amp;rev=1785703368&amp;do=diff</link>
        <description>Imaging Studies

Much of the advances in medicine in the last 20 years have been driven by new ways to look inside the body.  Imaging studies do not involve treatment typically, but may
require a drug to be given, especially for PET scans which involve label molecules which carry a very small amount of radiation.&lt;!----&gt;
&lt;p align=justify&gt; 
If you or a loved one is interested in participating in one of our trials, please 
contact us at (855) 829-8899 or use the form below.  One of our skilled Clin…</description>
    </item>
    <item rdf:about="https://www.neurozone.org/wiki/doku.php?id=ccm&amp;rev=1785703268&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-08-02T20:41:08+00:00</dc:date>
        <dc:creator>sflitman (sflitman@undisclosed.example.com)</dc:creator>
        <title>ccm - [Cerebral Cavernous Malformation] </title>
        <link>https://www.neurozone.org/wiki/doku.php?id=ccm&amp;rev=1785703268&amp;do=diff</link>
        <description>Cerebral Cavernous Malformation

Cavernous malformations are lesions in the brain which can grow and bleed, causing harm to the brain as a stroke, and irritability leading to seizures and epilepsy.  The sponsor has a novel AI-driven approach to developing new drugs and we are excited to participate in a trial of the their first drug in their pipeline offering potential hope for patients with CCM.&lt;!----&gt;
&lt;p align=justify&gt; 
If you or a loved one is interested in participating in one of our trials,…</description>
    </item>
    <item rdf:about="https://www.neurozone.org/wiki/doku.php?id=epilepsy&amp;rev=1665368525&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2022-10-10T02:22:05+00:00</dc:date>
        <dc:creator>sflitman (sflitman@undisclosed.example.com)</dc:creator>
        <title>epilepsy - [Epilepsy and Seizure Disorders] </title>
        <link>https://www.neurozone.org/wiki/doku.php?id=epilepsy&amp;rev=1665368525&amp;do=diff</link>
        <description>Epilepsy and Seizure Disorders


&lt;!--
We have no currently enrolling trials for this indication, but will update this page when a new trial becomes available.
--&gt;

 Condition(s)  Type of Drug  Phase  Add-On  Placebo  Duration 	Open Label Extension   Prolonged Seizures    Oral Spray Alprazolam    III    Yes    50%    18 weeks    4 years  
Response Form


&lt;p align=justify&gt; 
If you or a loved one is interested in participating in one of our trials, please 
contact us at (855) 829-8899 or use the fo…</description>
    </item>
</rdf:RDF>
